HHT Clinical Trial
Official title:
Tourniquet-Test in HHT
The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT.
The Tourniquet test is used as a diagnostic procedure for thrombocytopathies and vascular diseases. Currently, there is no evidence whether this test is also positive in hereditary haemorrhagic telangiectasia (HHT), a vasculopathy. The aim of this study was to investigate whether this non-invasive test could also be used as an additional diagnostic criterion in patients with HHT. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06039124 -
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
|
||
| Active, not recruiting |
NCT04150822 -
Hereditary Hemorrhagic Telangiectasia (HHT) Research Outcomes Registry
|
||
| Recruiting |
NCT03850964 -
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
|
Phase 2/Phase 3 | |
| Completed |
NCT01314274 -
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
|
Phase 2 | |
| Completed |
NCT02389959 -
Intranasal Bevacizumab for HHT-Related Epistaxis
|
Phase 4 | |
| Active, not recruiting |
NCT05550376 -
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
|